MedTrace Logo

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

NCT00539617 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-03-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Erlotinib

Tarceva single agent therapy: 150 mg/day PO

DRUG

5-fluorouracil

5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks

DRUG

Leucovorin

400 mg/m2 IV once every 2 weeks for 16 weeks

DRUG

Oxaliplatin

85 mg/m2 IV once every 2 weeks for 16 weeks

Sponsors & Collaborators

Principal Investigators

  • W. Michael Korn, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-05
Primary Completion
2011-05-12
Completion
2011-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539617 on ClinicalTrials.gov